Trials / Sponsors / Essen Biotech
Essen Biotech
Academic / Other · 17 registered clinical trials — 17 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | 2026-02-01 |
| Recruiting | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors Cancer, Sarcoma, Leukaemia | Phase 1 / Phase 2 | 2026-02-01 |
| Recruiting | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing | Phase 1 / Phase 2 | 2025-05-29 |
| Recruiting | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma | Phase 1 / Phase 2 | 2025-04-29 |
| Recruiting | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable | Phase 1 / Phase 2 | 2025-04-29 |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 1 / Phase 2 | 2025-04-29 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas Brain Tumor, Brain Metastases, Brain Cancer | Phase 1 / Phase 2 | 2024-10-20 |
| Recruiting | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer Colorectal Cancer, Colon Cancer, Rectum Cancer | Phase 1 / Phase 2 | 2024-09-29 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma | Phase 1 / Phase 2 | 2024-09-10 |
| Recruiting | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic | Phase 1 / Phase 2 | 2024-08-22 |
| Recruiting | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell | Phase 1 / Phase 2 | 2024-08-20 |
| Recruiting | Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease Sickle Cell Disease, Sickle-Cell Disease With Crisis | Phase 1 / Phase 2 | 2024-08-01 |
| Recruiting | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymp T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2024-07-10 |
| Recruiting | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell | Phase 1 / Phase 2 | 2024-07-10 |
| Recruiting | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases | Phase 1 / Phase 2 | 2024-07-10 |
| Recruiting | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML AML, Acute Myeloid Leukemia, AML, Adult Recurrent | Phase 1 / Phase 2 | 2024-07-10 |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute | Phase 1 / Phase 2 | 2024-05-29 |